Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT1VOHK)

• DTT Name: Potassium channel unspecific (KC)
• Gene Name: KC
• DTT Type: Successful target; [1]
• UniProt ID: NOUNIPROTAC
• TTD ID: T67952

Molecular Interaction Atlas (MIA) of This DTT

10 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amifampridine	DMK08L3	LambertEaton myasthenic syndrome	8C62	Approved	[2]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[1]
Dalfampridine	DMM0PDO	Multiple sclerosis	8A40	Approved	[3]
Diazoxide	DML1538	Congenital hyperinsulinism	5A4Y	Approved	[1]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[1]
Dronedarone	DMA8FS5	Angina pectoris	BA40	Approved	[4]
Ibutilide	DMKXY2R	Atrial fibrillation	BC81.3	Approved	[1]
Minoxidil	DMA2Z4F	Alopecia	ED70	Approved	[1]
Nateglinide	DMLK2QH	Diabetic complication	5A2Y	Approved	[1]
Pinacidil	DMRADYL	High blood pressure	BA00	Approved	[1]

16 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Andolast	DMX36BH	Rhinitis	FA20	Phase 3	[5]
Azimilide	DMUIBV8	Atrial fibrillation	BC81.3	Phase 3	[6]
ATI-2042	DMWP59B	Atrial fibrillation	BC81.3	Phase 2	[7]
AZD-7009	DMIBXK0	Atrial fibrillation	BC81.3	Phase 2	[8]
Bimakalim	DMBRL19	Angina pectoris	BA40	Phase 2	[9]
HBI-3000	DM74ZKN	Heart arrhythmia	BC65	Phase 2	[10]
K-201	DMZCVD7	Atopic dermatitis	EA80	Phase 2	[11]
MSH-1001	DMUM370	Ocular hypertension	9C61.01	Phase 2	[12]
RP-49356	DM4N6PF	Hypertension	BA00-BA04	Phase 2	[13]
YM-934	DM7KR4C	Angina pectoris	BA40	Phase 2	[14]
AVE0118	DMSR91U	Obstructive sleep apnea	7A41	Phase 1	[15]
CLP-1004	DM2QBMI	Hypertension	BA00-BA04	Phase 1	[16]
Iptakalim	DMHW1LI	Hypertension	BA00-BA04	Phase 1	[17]
Nibentan	DM8J3WE	Cardiac arrhythmias	BC9Z	Phase 1	[18]
NS-8	DMX8LY4	Urinary incontinence	MF50.2	Phase 1	[19]
UK-66914	DMO8Z1D	Cardiac arrhythmias	BC9Z	Phase 1	[20]

46 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Levcromakalim	DMNS4TK	Chronic obstructive pulmonary disease	CA22	Discontinued in Preregistration	[21]
Acecainide	DMKM543	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 3	[22]
Alinidine	DMV2Y6L	Angina pectoris	BA40	Discontinued in Phase 3	[23]
Almokalant	DMV3PEA	Cardiac arrhythmias	BC9Z	Discontinued in Phase 3	[24]
BMS-204352	DMFZNLH	Nerve injury	ND56.4	Discontinued in Phase 3	[25]
Ambasilide	DMA57O4	Cardiac arrhythmias	BC9Z	Discontinued in Phase 2	[26]
BMS-180448	DMVBGIT	Angina pectoris	BA40	Discontinued in Phase 2	[27]
BRL-32872A	DMRKBIU	Cardiac arrhythmias	BC9Z	Discontinued in Phase 2	[28]
BRL-55834	DM0WG4U	Chronic obstructive pulmonary disease	CA22	Discontinued in Phase 2	[29]
E-4031	DMU872N	Cardiac arrhythmias	BC9Z	Discontinued in Phase 2	[30]
JTV-506	DMM8UNL	Angina pectoris	BA40	Discontinued in Phase 2	[31]
KCO-912	DMC30N4	Chronic obstructive pulmonary disease	CA22	Discontinued in Phase 2	[32]
KW-7158	DMJNSML	Urinary incontinence	MF50.2	Discontinued in Phase 2	[33]
P-1075	DM02ANM	Hypertension	BA00-BA04	Discontinued in Phase 2	[34]
Risotilide	DMNRGB7	Heart arrhythmia	BC65	Discontinued in Phase 2	[35]
Y-27152	DMO90RN	Angina pectoris	BA40	Discontinued in Phase 2	[36]
ZD-0947	DMS95DX	Overactive bladder	GC50.0	Discontinued in Phase 2	[37]
ZD-6169	DMVBL25	Urinary incontinence	MF50.2	Discontinued in Phase 2	[37]
Emakalim	DM2V5XP	Angina pectoris	BA40	Discontinued in Phase 1	[38]
KR-30450	DMMD6LR	Hypertension	BA00-BA04	Discontinued in Phase 1	[39]
NTC-801	DM1QZKS	Atrial fibrillation	BC81.3	Discontinued in Phase 1	[40]
Rilmakalim	DMBQZTO	Chronic obstructive pulmonary disease	CA22	Discontinued in Phase 1	[41]
Ro-31-6930	DMAJDPN	Hypertension	BA00-BA04	Discontinued in Phase 1	[42]
SDZ-PCO-400	DMZHOYM	Asthma	CA23	Discontinued in Phase 1	[43]
SR-47063	DMAICVN	Cardiac arrhythmias	BC9Z	Discontinued in Phase 1	[44]
Symakalim	DMSPBJ9	Hypertension	BA00-BA04	Discontinued in Phase 1	[45]
AL-0671	DMRYJ40	Arteriosclerosis	BD40	Terminated	[46]
AWD-23-111	DMD8ZM1	Heart arrhythmia	BC65	Terminated	[47]
E-4080	DMZ1JKX	Angina pectoris	BA40	Terminated	[48]
ICI-181037	DM0XU4P	Heart arrhythmia	BC65	Terminated	[49]
KC-399	DMD0FNH	Alopecia	ED70	Terminated	[50]
Ki-1769	DMQXPJB	Hypertension	BA00-BA04	Terminated	[51]
NS-004	DMCHLJ4	Hypertension	BA00-BA04	Terminated	[52]
NS-1546	DM75DZ1	Major depressive disorder	6A70.3	Terminated	[53]
NS-1608	DMYV9M1	Cerebrovascular ischaemia	8B1Z	Terminated	[54]
Org-20781	DM95QG2	Heart arrhythmia	BC65	Terminated	[55]
RP-66784	DM2GV78	Angina pectoris	BA40	Terminated	[56]
S-1389	DMDQGFR	Heart arrhythmia	BC65	Terminated	[57]
SB-237376	DMBCANZ	Arrhythmia	BC9Z	Terminated	[58]
TCV-295	DMCFGS6	Hypertension	BA00-BA04	Terminated	[59]
TERIKALANT	DM2X5R6	Cardiac arrhythmias	BC9Z	Terminated	[60]
UR-8225	DMJC82N	Asthma	CA23	Terminated	[61]
UR-8308	DM6C7WJ	Asthma	CA23	Terminated	[62]
UR-8328	DM4KOTA	Asthma	CA23	Terminated	[63]
WAY-123223	DMMOS8G	Heart arrhythmia	BC65	Terminated	[64]
YM-099	DMDXLG2	Hypertension	BA00-BA04	Terminated	[65]

8 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CGS-7181	DMZKS6Q	Discovery agent	N.A.	Investigative	[66]
HMR1883	DMNXR17	Discovery agent	N.A.	Investigative	[67]
L 691121	DMB73Y4	Discovery agent	N.A.	Investigative	[68]
MJ-451	DMMP6YH	Discovery agent	N.A.	Investigative	[69]
RP-66471	DMR4O3I	Discovery agent	N.A.	Investigative	[70]
Trecetilide fumarate	DME94KO	Cardiac arrhythmias	BC9Z	Investigative	[71]
WAY-125971	DMCSZG0	Discovery agent	N.A.	Investigative	[64]
Y-26763	DMZKPSQ	Discovery agent	N.A.	Investigative	[72]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [2] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [3] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [4] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [5] BK channel modulators: a comprehensive overview. Curr Med Chem. 2008;15(11):1126-46.
• [6] Azimilide. Drugs. 2000 Feb;59(2):271-7; discussion 278-9.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Rapid slowing of the atrial fibrillatory rate after administration of AZD7009 predicts conversion of atrial fibrillation. J Electrocardiol. 2014 May-Jun;47(3):316-23.
• [9] Lack of anti-ischemic efficacy of the potassium channel opener bimakalim in patients with stable angina pectoris. Cardiovasc Drugs Ther. 2004 Jan;18(1):37-46.
• [10] Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85.
• [11] Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy
• [12] KR-31378, a potassium-channel opener, induces the protection of retinal ganglion cells in rat retinal ischemic models. J Pharmacol Sci. 2009 Apr;109(4):511-7.
• [13] Effects of pinacidil, RP 49356 and nicorandil on ATP-sensitive potassium channels in insulin-secreting cells. Br J Pharmacol. 1990 Mar;99(3):487-92.
• [14] Potassium channel opener, YM 934, inhibits neurogenic plasma leakage in guinea pig airways. Am J Respir Crit Care Med. 1994 Nov;150(5 Pt 1):1379-83.
• [15] Neurogenic contraction induced by the antiarrhythmic compound, AVE 0118, in rat small mesenteric arteries.Basic Clin Pharmacol Toxicol.2014 Oct;115(4):315-20.
• [16] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036783)
• [17] Iptakalim: A novel multi-utility potassium channel opener. J Pharmacol Pharmacother. 2012 Jan;3(1):12-4.
• [18] Nibentan -- a drug for pharmacological cardioversion of persistent atrial fibrillation. Kardiologiia. 2005;45(3):19-23.
• [19] Stimulation of large-conductance calcium-activated potassium channels inhibits neurogenic contraction of human bladder from patients with urinary symptoms and reverses acetic acid-induced bladder hyperactivity in rats. Eur J Pharmacol. 2014 Jul 15;735:68-76.
• [20] Electrophysiologic properties of UK-66,914, a novel class III antiarrhythmic agent. J Cardiovasc Pharmacol. 1991 Mar;17(3):376-85.
• [21] The potassium channel opener levcromakalim causes expansive remodelling of experimental vein grafts. J Vasc Surg. 2006 Jul;44(1):159-65.
• [22] Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias. Drugs. 1990 May;39(5):720-40.
• [23] Decrease in bradycardic effect of AQ-A 39 and alinidine in guinea-pig sinoatrial node depolarized by high external K+-concentration. Naunyn Schmiedebergs Arch Pharmacol. 1984 Dec;328(2):210-3.
• [24] Effect of almokalant, a selective potassium channel blocker, on the termination and inducibility of paroxysmal supraventricular tachycardias: a study in patients with Wolff-Parkinson-White syndrome and atrioventricular nodal reentrant tachycardia.Almokalant PSVT Study Group.J Cardiovasc Pharmacol.1995 Aug;26(2):198-206.
• [25] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [26] Ambasilide prolongs the action potential and blocks multiple potassium currents in human atrium. J Cardiovasc Pharmacol. 1999 May;33(5):762-71.
• [27] The novel cardioprotective agent BMS-180448 activates a potassium conductance in cardiac and vascular smooth muscle. Naunyn Schmiedebergs Arch Pharmacol. 1996 Oct;354(4):444-51.
• [28] Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile... J Pharmacol Exp Ther. 1996 Feb;276(2):637-46.
• [29] Comparison of the airways relaxant and hypotensive potencies of the potassium channel activators BRL 55834 and levcromakalim (BRL 38227) in vivo in guinea-pigs and rats. Br J Pharmacol. 1993 Aug;109(4):1133-9.
• [30] Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes.Br J Pharmacol.2012 Jan;165(2):467-78.
• [31] Effects of the new potassium channel opener JTV-506 on coronary vessels in vitro and in vivo. Arzneimittelforschung. 1999 Mar;49(3):199-206.
• [32] KCO912: a potent and selective opener of ATP-dependent potassium (K(ATP)) channels which suppresses airways hyperreactivity at doses devoid of card... Naunyn Schmiedebergs Arch Pharmacol. 2002 Mar;365(3):220-30.
• [33] KW-7158 [(2S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide] enhances A-type K+... J Pharmacol Exp Ther. 2004 Jul;310(1):159-68.
• [34] The effects of potassium channel opener P1075 on the human saphenous vein and human internal mammary artery. J Cardiovasc Pharmacol. 2011 Jun;57(6):648-55.
• [35] Electrophysiological effects of left ventricular hypertrophy. Effect of calcium and potassium channel blockade. Circulation. 1991 Jun;83(6):2067-75.
• [36] Pharmacokinetics and safety of a novel, long-acting, prodrug-type potassium channel opener, Y-27152, in healthy volunteers. J Clin Pharmacol. 1996 May;36(5):439-51.
• [37] Effects of ZD6169 and ZD0947, 2 potassium adenosine triphosphate channel openers, on bladder function of spinalized rats. J Urol. 2002 Aug;168(2):837-42.
• [38] Therapeutic potential of potassium channel activators in coronary heart disease. Eur Heart J. 1994 Aug;15 Suppl C:82-8.
• [39] Cardioprotective effects of KR-30450, a novel K+(ATP) opener, and its major metabolite KR-30818 on isolated rat hearts. Jpn J Pharmacol. 1998 Jan;76(1):65-73.
• [40] Effects of the selective KACh channel blocker NTC-801 on atrial fibrillation in a canine model of atrial tachypacing: comparison with class Ic and III drugs. J Cardiovasc Pharmacol. 2014 May;63(5):421-7.
• [41] Hypotonic stress increases efficacy of rilmakalim, but not pinacidil, to activate ATP-sensitive K(+) current in guinea pig ventricular myocytes. J Pharmacol Sci. 2004 Jun;95(2):189-95.
• [42] Evaluation of the bronchodilator properties of Ro 31-6930, a novel potassium channel opener, in the guinea-pig. Br J Pharmacol. 1990 Jun;100(2):289-94.
• [43] Effects of a potassium channel opener (SDZ PCO 400) on guinea-pig and human pulmonary airways. Br J Pharmacol. 1992 Jun;106(2):423-9.
• [44] Vasorelaxant effects of the potassium channel opener SR 47063 on the isolated human saphenous vein and rat aorta. Braz J Med Biol Res. 2000 Aug;33(8):961-6.
• [45] Synthesis and antihypertensive activity of 4-(diazabicyclo[4.1.0]-heptenyloxy)benzopyran derivatives and their analogues. Chem Pharm Bull (Tokyo). 1998 Apr;46(4):602-9.
• [46] A possible mechanism of action of a new potassium channel opener, AL0671, on lipid metabolism in obese Zucker rats. J Pharmacol Exp Ther. 1994 Dec;271(3):1666-71.
• [47] The new antiarrhythmic substance AWD 23-111 inhibits the delayed rectifier potassium current (IK) in guinea pig ventricular myocytes. Pharmazie. 1999 Jan;54(1):61-8.
• [48] Ionic currents involved in vasodilating actions of E4080, a newly synthesized bradycardia-inducing agent, in dispersed smooth muscle cells of the rabbit portal vein. J Pharmacol Exp Ther. 1991 Dec;259(3):1396-403.
• [49] ICI 181,037: a novel eukalemic diuretic with antiarrhythmic activity. Jpn J Pharmacol. 1991 Nov;57(3):263-77.
• [50] Action of KC-399, a newly synthesized potassium channel opener, on mechanical activity and 86Rb efflux in rat aorta. J Cardiovasc Pharmacol. 1994 Feb;23(2):220-6.
• [51] Vasorelaxant action of Ki1769, a new pyridinecarboximidamide, in isolated porcine coronary artery. Eur J Pharmacol. 1993 Sep 14;241(2-3):177-81.
• [52] Effects of K+ channel inhibitors and antagonists on NS-004 evoked relaxations in guinea-pig isolated trachea. Fundam Clin Pharmacol. 1997;11(1):78-82.
• [53] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006187)
• [54] Modulation of the Ca(2+)-dependent K+ channel, hslo, by the substituted diphenylurea NS 1608, paxilline and internal Ca2+. Neuropharmacology. 1996;35(7):903-14.
• [55] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003350)
• [56] Syntheses and biological activities of potent potassium channel openers derived from (+/-)-2-oxo-1-pyridin-3-yl-cyclohexanecarbothioic acid methylamide: new potassium channel openers. J Med Chem. 1993 May 28;36(11):1604-12.
• [57] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000214)
• [58] Electrophysiologic effects of SB-237376: a new antiarrhythmic compound with dual potassium and calcium channel blocking action. J Cardiovasc Pharmacol. 2003 Mar;41(3):414-21.
• [59] Antihypertensive and cardiovascular effects of a new potassium channel opener, TCV-295, in rats and dogs. J Cardiovasc Pharmacol. 1994 Dec;24(6):929-36.
• [60] Terikalant, an inward-rectifier potassium channel blocker, does not abolish the cardioprotection induced by ischemic preconditioning in the rat. J Mol Cell Cardiol. 1998 Sep;30(9):1817-25.
• [61] Effects of the novel potassium channel opener, UR-8225, on contractile responses in rat isolated smooth muscle. Br J Pharmacol. 1993 Nov;110(3):1165-71.
• [62] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005294)
• [63] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005293)
• [64] Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives. J Med Chem. 1991 Nov;34(11):3212-28.
• [65] Potassium channel-opening and vasorelaxant profiles of a novel compound YM099 in rat isolated portal vein and rabbit isolated aorta. Arch Int Pharmacodyn Ther. 1994 May-Jun;327(3):330-43.
• [66] Molecular mechanism of pharmacological activation of BK channels
• [67] Clamikalant (Aventis). IDrugs. 2000 Nov;3(11):1353-7.
• [68] Embryotoxic effects of L-691,121, a class III antiarrhythmic agent, in rats. Arch Toxicol. 1994;69(1):65-71.
• [69] Pharmacological characteristics of MJ-451, a new benzopyran- derived ATP-sensitive potassium channel opener, in guinea pig isolated trachea. Pharmacology. 1998 Dec;57(6):314-22.
• [70] Potassium channel opener, RP 66471, induces membrane depolarization of rat liver mitochondria. Biochem Biophys Res Commun. 1995 Feb 6;207(1):126-32.
• [71] IKr channel blockers: novel antiarrhythmic agents. Curr Med Chem Cardiovasc Hematol Agents. 2003 Oct;1(3):203-23.
• [72] Y-26763: ATP-sensitive K+ channel activation and the inhibition of insulin release from human pancreatic beta-cells. Eur J Pharmacol. 2004 Feb 20;486(2):133-9.